AstraZeneca launches LabTalk

AstraZeneca introduces an online forum for the scientific community.

AstraZeneca launched a new science blog, LabTalk, providing an online forum where scientists can discuss cutting-edge science and innovation.

LabTalk offers a platform for scientists to share innovative ideas and approaches. From discovery in the lab, to making a meaningful difference in the lives of patients, LabTalk seeks to foster the creativity and innovation shared amongst scientists in an easy-to-use, online forum.

“The value of ‘LabTalk’ is not only to raise the profile of innovative science, but it also gives AstraZeneca the opportunity to hear from our peers,” said Oliver Stohlmann, vice president of R&D Communications. “Over time we hope to build up a rich library of content that will help tell the R&D story, both from AstraZeneca’s and others’ perspectives. This is something we’ve started with the recent ‘Letters from the Lab’ features, but with LabTalk we have the functionality to also engage with readers. What’s more, it will create a platform to showcase the great work of our scientists, making our work more transparent to potential collaborators.”

Head over to www.labtalk.astrazeneca.com and let us know what you think.

AstraZeneca Careers launches Pinterest page

AstraZeneca Careers has recently launched a profile on Pinterest as an opportunity to leverage one of the fastest-growing social media platforms on the internet.

The profile has 18 boards such as Applications and Interviews, Community Involvement, Internships and Students, and US Military Veterans. The page boards include information about AZ’s culture, employee activities, tips for interviewing and applications, etc.

In other social media efforts, AZ Careers recently launched a microsite designed for US military veterans transitioning from military life to the work force. You can also follow AZ Careers on Facebook and Twitter.

AZ Careers recognizes the importance of social media as a recruitment tool for job-seekers and we are excited about the opportunity to interact with potential candidates.

Visit the AZ Careers Pinterest page at www.pinterest.com/astrazenecajobs.

How AstraZeneca uses social media in the US

Patients are increasingly turning to social media for answers to health questions – and those conversations are held on community sites significantly more frequently than on sites run by health industry organizations, according to a new report by PricewaterhouseCoopers.

The report found that community sites – such as those run by patient groups – had 24 times more social media activity on average than any of the health companies studied over a one-week period. It also found that health businesses are more likely to listen via social media than fully engage.

This appears to be a fairly accurate reflection of the state of heathcare social media, as we seek to use new communication channels while respecting patient privacy and adhere to laws and regulations governing our industry.

With the release of this report, it would seem to be a useful time to remind our readers about our presence on social media in the United States – along with how we approach it as a business.

AstraZeneca and Social Media

First, there is this blog, of course. We use AZ Health Connections for four primary purposes:

  • Shed light on how we do business, such as through question and answer stories with company leaders.
  • Comment and engage on external issues, such as public policy or industry trends.
  • Share corporate news and information.
  • Amplify stories in the media about AstraZeneca.

Second, AstraZeneca US is on Twitter. Click here to visit our page.

Third, Facebook, where people can share, like and comment on our posts. We explained why we are on Facebook here.

And, finally, our YouTube channel, which we largely use to host videos for this blog.

Social Media Principles

AstraZeneca seeks to follow five principles that should be at the core of any company engagement in social media:

1. Truth and Accuracy: Content must be created, developed, or made available that is truthful, balanced, accurate, and not misleading.

2. Be Respectful: Encourage product sponsor participation that respects the interests of patients, caregivers, and health care providers, particularly related to matters of privacy and the primacy of the patient/physician relationship.

3. Protect and Advance Patient Health: Facilitate patient access to quality information for use with their physician to improve their health and protect patients through encouraging accurate and timely reporting on medicine safety.

4. Transparency: Any product sponsor participation should be accomplished in a manner that, at all times, is entirely transparent to other participants as to the role of product sponsors as participants in online discussion.

5. Respect the Views of Others: Acknowledge that patients, caregivers, clinicians and others who participate in social media have their own opinions and that, when they differ from those of the product sponsor, it is not the role of a product sponsor to censor or limit these views but to add the product sponsor’s own views to the discussion.

We look forward to improving our capabilities in the social media space – and hearing from you on how we can most appropriately and effectively engage and communicate with those who are impacted by our business.

Survey: How our scientists use social media

When not in the lab, our scientists also use social media to engage.

We recently surveyed our scientists and some of their partners around the world: How are you using social media for science-related activities?

The results show that respondents believe there is a place for social media in science, especially in the areas of information sharing, collaboration, knowledge building and networking. So far, our scientists and their external partners are particularly active in professional networks, wikis and blogs but less so on online forums and microblogging outlets such as Twitter.

“Social media are like any medium of communications,” one respondent wrote in the comments. “Saying that social media are not important is isolating you as a scientist … (which) rarely leads to new science.”

Here are some of the highlights of the survey, based on 372 responses*:

How much value does social media deliver to scientists?

  • Absolutely essential: 6 percent
  • Very valuable: 18 percent
  • Valuable: 33 percent
  • Somewhat valuable: 35 percent
  • Minimum value: 8 percent

What is the value in social media?

  • Information sharing/collaboration: 62 percent
  • Knowledge building: 61 percent
  • Networking: 61 percent
  • Participating in discussion: 33 percent
  • Getting the message out/thought leadership: 10 percent

Do you participate in social media? And why?

  • Yes: 71 percent
  • Science-related activity: 71 percent
  • Personal activity: 69 percent

How do you use social media?

  • Read/watch online content: 61 percent
  • Post comments: 18 percent
  • Join conversations: 17 percent
  • Update status online: 10 percent
  • Generate content: 7 percent

What kinds of channels do you participate in (among those using social media)?

  • Professional networks: 79 percent
  • Wikis: 53 percent
  • Blogs: 50 percent
  • Yammer: 48 percent
  • Social networks: 25 percent
  • Video sharing sites: 23 percent
  • Online forums/roundtables: 21 percent
  • Presentation sharing sites: 17 percent
  • Photo sharing sites: 14 percent
  • Microblogging: 9 percent

We will use these results to help inform our R&D social media communications strategies for 2012 and beyond.

In the meantime, how do you think social media can be used to promote research and development in the pharmaceutical industry?

*95 percent of the results came from AZ scientists, with the rest from their external network of scientists. 37 percent of the respondents were from the UK, followed by 31 percent from Sweden and 25 percent from the United States. The additional 7 percent were from India, Canada and other western European nations.

AstraZeneca recognized for engagement through social media

AstraZeneca uses social media to engage stakeholders in conversations about important healthcare issues

How are healthcare organizations using social media to engage their stakeholders in conversations about those issues most important to them?

Creation Healthcare’s 2012 Healthcare Engagement Strategy awards show how organizations are using a variety of social media tools to build new avenues of important dialogue and how they are measuring the outcomes of these efforts.

AstraZeneca is proud to be among the organizations recognized this year. To learn more about our #rxsave Twitter chat on patient assistance programs, please visit the Open Dialogue Award page here.

Jennifer McGovern, director of AstraZeneca’s prescription savings programs, shared the team’s rationale for hosting the Twitter chat. “We’ve been engaging with advocates for many years talking about strategies for reaching eligible patients. Using Twitter was really just a way to expand this ongoing conversation and the response was overwhelmingly positive.”

FDA issues social media guidance

On Tuesday, the Food and Drug Administration issued “Guidance for Industry Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices.” This draft guidance updates and clarifies FDA’s policies on unsolicited requests for off-label information, including those that firms may encounter through emerging electronic media.

Guidance from the FDA is an important step, as it shows the FDA’s attention to these changing mediums. These channels help us listen to and participate in important conversations about health care in the United States. Therefore, we applaud the FDA for providing guidance and look forward to the evolution of health care conversation in digital media.

In advance of this guidance, AstraZeneca released a white paper back in February that examined the pharmaceutical industry’s use of social media to discuss medicines and diseases, while taking a look at the roles – current and future – the industry and the FDA should play in these ever growing communication channels.

Two primary themes are captured in the paper:

  1. Social media is a fundamental part of advancing public health.
  2. Pharmaceutical companies have a responsibility to engage more fully in social media.

Moving forward, we plan to work within the regulatory framework to ensure we are viewed as a trusted source of information about our medicines in the social media space, which includes this blog, @AstraZenecaUS on Twitter, and AstraZeneca’s Facebook page.

AstraZeneca is staying on Facebook

As the Washington Post noted over the weekend, some biopharmaceutical companies are removing their corporate or branded Facebook pages in light of changes the social network made to its commenting policies.

We are keeping our Facebook page for the US business.

Why? Because our presence on Facebook – along with this blog and @AstraZenecaUS and @AZHelps on Twitter – helps us listen to and participate in important conversations about health care in the United States.

Given regulatory restrictions, however, we do face some challenges in fully engaging on Facebook or through other social media channels. Some of those challenges are laid out in our commenting policy, which details when and why we may delete some comments from our posts or wall.

So take a look and consider liking us on Facebook, and we look forward to continuing the conversation with you all.

AstraZeneca launches Click-to-Chat

AstraZeneca entered new territory recently by launching “click-to-chat” for two of its medicines—CRESTOR® (rosuvastatin calcium) and NEXIUM® (esomeprazole magnesium) — allowing patients and caregivers to talk real-time in an instant messaging format to trained individuals at the AstraZeneca Information Center.

The live chat feature is easy to use. To access it, go to the “Contact Us” page of the CRESTOR and NEXIUM websites and click on “Click to Chat.”


A pop-up window will appear and you will be asked to fill in your name and question. Upon completion of this information, click on “Click to Chat” again.

Another pop-up window will appear and it will provide an approximate wait time. Then you will be connected directly to an AstraZeneca Information Center representative for a live chat.

Upon completion of your chat, you will be asked to participate in an online survey. We hope you take the time to tell us about your experience.

This new feature empowers consumers to have more flexibility when interacting with AstraZeneca representatives and easier access to information about CRESTOR and NEXIUM through the convenience of an online chat.

For more information about click-to-chat, please click here.

- By Rachelle Benson

1171900 4/11

Using the #rxsave Twitter chat to help patients

First, thank you to everyone who participated in last night's #rxsave Twitter chat on prescription savings programs.

From our perspective, the most impressive aspect of the chat was the sheer number of good ideas generated and shared by patients, advocates, doctors, pharmacists and those who were simply interested in a biopharmaceutical company engaging in such a discussion.

Jennifer McGovern, who runs our savings program and moderated the discussion, says her team is already taking some of the ideas and feedback from the chat to find new ways to better reach patients who may benefit from the AZ&Me savings program.

That, in the end, will make the whole conversation worth it.

- By Tony Jewell